HC Wainwright restated their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS – Free Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $120.00 price objective on the stock.
Several other research firms also recently commented on CMPS. Royal Bank of Canada began coverage on COMPASS Pathways in a report on Tuesday, July 23rd. They issued an outperform rating and a $23.00 price objective for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of COMPASS Pathways in a report on Friday, June 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average target price of $43.00.
Get Our Latest Research Report on COMPASS Pathways
COMPASS Pathways Stock Up 2.3 %
COMPASS Pathways (NASDAQ:CMPS – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). On average, equities analysts predict that COMPASS Pathways will post -2.24 EPS for the current fiscal year.
Institutional Investors Weigh In On COMPASS Pathways
Several institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. bought a new stake in shares of COMPASS Pathways in the second quarter worth about $664,000. Blue Trust Inc. bought a new stake in COMPASS Pathways in the second quarter worth $81,000. Virtu Financial LLC bought a new stake in shares of COMPASS Pathways in the 1st quarter worth about $201,000. Tidal Investments LLC boosted its position in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after buying an additional 5,795 shares during the period. Finally, Kennedy Capital Management LLC purchased a new position in COMPASS Pathways during the 1st quarter valued at $139,000. Institutional investors own 46.19% of the company’s stock.
COMPASS Pathways Company Profile
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Featured Stories
- Five stocks we like better than COMPASS Pathways
- Are Penny Stocks a Good Fit for Your Portfolio?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.